DARWIN AG Logo

DARWIN AG

7V0 | MU

Overview

Corporate Details

ISIN(s):
DE000A3C35W0
LEI:
391200XJOD6U0EW7OE14
Country:
Germany
Address:
Brienner Str. 7, 80333 München
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

DARWIN AG is a biotechnology company that develops personalized products, services, and therapies based on unique biological data. The company integrates advanced laboratory analysis of the human genome and metabolome with proprietary artificial intelligence platforms to gain deep insights into individual health. Its core offerings include personalized supplements and cosmetics, genetic reports with actionable health plans, and services for the optimization of medical therapies, including IVF and personalized drug development. Operating as a technology-driven group with multiple brands, DARWIN AG serves both direct-to-consumer (B2C) and business-to-business (B2B) markets, partnering with medical professionals and other companies. The company's unique 'Analyse. Learn. Solve.' approach enables the creation of highly tailored solutions at an industrial scale.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for DARWIN AG. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-07-30 00:00
Annual Report
Datum:30.07.2025
German 384.3 KB
2024-10-01 00:00
Annual Report
Konzernabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
German 255.3 KB
2024-09-10 00:00
Annual / Quarterly Financial Statement
Jahresabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
German 69.8 KB
2023-09-20 00:00
Board/Management Information
Ergänzung der Veröffentlichung vom 05.01.2023
German 8.2 KB
2023-08-11 00:00
Annual / Quarterly Financial Statement
Jahresabschluss zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022
German 56.9 KB
2023-06-06 00:00
Annual / Quarterly Financial Statement
Konzernabschluss zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022
German 217.2 KB
2023-03-21 00:00
Annual / Quarterly Financial Statement
Jahresabschluss zum Geschäftsjahr vom 15.03.2021 bis zum 31.12.2021
German 44.0 KB
2023-01-05 00:00
Annual / Quarterly Financial Statement
Ergänzt am 20.09.2023
German 169.9 KB

Automate Your Workflow. Get a real-time feed of all DARWIN AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for DARWIN AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Initiator Pharma A/S Logo
Clinical-stage firm developing drugs for nervous system disorders like ED & trigeminal neuralgia.
Denmark INIT
Innate Pharma Logo
Clinical-stage biotech developing antibodies that harness NK cells to fight cancer.
France IPH
IntegraGen Logo
Genomics specialist providing analyses & SaaS for cancer/rare diseases to researchers & labs.
France ALINT
Inventiva Logo
Develops oral small molecule therapies for fibrosis, oncology, and lysosomal storage disorders.
France IVA
IRLAB Therapeutics Logo
Developing novel treatments for neurodegenerative conditions like Parkinson's disease.
Sweden IRLAB
Isofol Medical Logo
Clinical-stage biotech developing a drug to enhance chemotherapy efficacy for colorectal cancer.
Sweden ISOFOL
IXICO PLC Logo
AI-powered neuroimaging and biomarker analytics for neurological clinical trials.
United Kingdom IXI
J. Molner AS Logo
A CDRO specializing in generic injectable and topical drugs for the North American market.
Estonia JML
Kadimastem Ltd. Logo
Develops off-the-shelf cell therapies for neurodegenerative and metabolic diseases.
Israel KDST
Kancera Logo
Develops drugs targeting the fractalkine axis for severe inflammation and resistant cancers.
Sweden KAN